ATE364399T1 - Einen zns-penetrierenden nk-1- rezeptorantagonisten und ein angstlösendes oder antidepressives mittel enthaltende zusammensetzung zur behandlung von depression und angst - Google Patents

Einen zns-penetrierenden nk-1- rezeptorantagonisten und ein angstlösendes oder antidepressives mittel enthaltende zusammensetzung zur behandlung von depression und angst

Info

Publication number
ATE364399T1
ATE364399T1 AT00309908T AT00309908T ATE364399T1 AT E364399 T1 ATE364399 T1 AT E364399T1 AT 00309908 T AT00309908 T AT 00309908T AT 00309908 T AT00309908 T AT 00309908T AT E364399 T1 ATE364399 T1 AT E364399T1
Authority
AT
Austria
Prior art keywords
receptor antagonist
cns
anxiety
depression
anxiologiant
Prior art date
Application number
AT00309908T
Other languages
English (en)
Inventor
Susan Beth Sobolov-Jaynes
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE364399T1 publication Critical patent/ATE364399T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00309908T 1999-11-10 2000-11-08 Einen zns-penetrierenden nk-1- rezeptorantagonisten und ein angstlösendes oder antidepressives mittel enthaltende zusammensetzung zur behandlung von depression und angst ATE364399T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16469299P 1999-11-10 1999-11-10

Publications (1)

Publication Number Publication Date
ATE364399T1 true ATE364399T1 (de) 2007-07-15

Family

ID=22595647

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00309908T ATE364399T1 (de) 1999-11-10 2000-11-08 Einen zns-penetrierenden nk-1- rezeptorantagonisten und ein angstlösendes oder antidepressives mittel enthaltende zusammensetzung zur behandlung von depression und angst

Country Status (9)

Country Link
US (1) US20040220274A1 (de)
EP (1) EP1099446B1 (de)
JP (1) JP2001139490A (de)
AT (1) ATE364399T1 (de)
BR (1) BR0005319A (de)
CA (1) CA2324813A1 (de)
DE (1) DE60035162T2 (de)
ES (1) ES2285995T3 (de)
MX (1) MXPA00011035A (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411946A1 (de) * 2001-07-20 2004-04-28 Pfizer Products Inc. Verwendung von nk-1 rezeptor antagonisten zur beeinflussung unerwünschten verhaltens bei hunden, katzen und pferden
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
JP2007502856A (ja) * 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
CN1819821B (zh) 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
AU726745B2 (en) * 1996-10-07 2000-11-16 Merck Sharp & Dohme Limited CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent

Also Published As

Publication number Publication date
DE60035162D1 (de) 2007-07-26
EP1099446A3 (de) 2003-03-26
DE60035162T2 (de) 2008-02-14
JP2001139490A (ja) 2001-05-22
CA2324813A1 (en) 2001-05-10
EP1099446B1 (de) 2007-06-13
MXPA00011035A (es) 2002-05-23
ES2285995T3 (es) 2007-12-01
US20040220274A1 (en) 2004-11-04
BR0005319A (pt) 2001-07-17
EP1099446A2 (de) 2001-05-16

Similar Documents

Publication Publication Date Title
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
MY116002A (en) Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
PT2194049E (pt) N-óxidos de derivados de n-fenil-2-pirimidina-amina
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
ATE234835T1 (de) Trovafloxacin enhaltende suspensionen zur oralen anwendung
PT1358177E (pt) Tratamento de desordens afectivas atraves da accao combinada de um agonista do receptor nicotinico e uma substancia manoaminergica
BR0311898A (pt) Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
WO2004067027A3 (en) Osteogenic composition
EP1213031A3 (de) Kombinationstherapie zur Behandlung von Depression, Angstzuständen und Psychosen, die ein antidepressives und/oder anxiolytisches Mittel und einen D4-Rezeptor-Hemmer enthält
DE60035162D1 (de) Einen ZNS-penetrierenden NK-1-Rezeptorantagonisten und ein angstlösendes oder antidepressives Mittel enthaltende Zusammensetzung zur Behandlung von Depression und Angst
BR0104345A (pt) Tratamento combinado para a depressão e ansiedade
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
ATE288756T1 (de) Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties